Literature DB >> 101464

Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

M M Lieberman.   

Abstract

The preparation, properties, and immunogenicity of ribosomal vaccines from Pseudomonas aeruginosa are described. These preparations, containing protein and RNA, were tested for immunogenicity by active immunization of mice and subsequent challenge with homologous, live bacteria. The results demonstrated that vaccines prepared from a majority of serotypes used were immunogenic, i.e., afforded 60 to 100% mouse protection against a challenge inoculum containing 8 to 50 50% lethal doses. In some cases vaccine doses as low as 1 microgram of RNA provided 100% mouse protection. Molecular sieve chromatography of a highly immunogenic ribosomal preparation on Sepharose 4B demonstrated the presence of two molecular weight fractions: (i) peak A, an excluded peak (thus having a molecular weight of at least 2 times 10(7)), and (ii) peak B, considerably retarded, with an elution position corresponding to a molecular weight of about 2.2 X 10(6), approximating that of typical 70S ribosomes. Both peaks A and B were immunogenic; however, the immunogenicity of peak A was greater (i.e., a smaller immunizing dose was required) than that of peak B. Peak A was shown to contain components of lipopolysaccharide in addition to protein and RNA (which comprised 80% of the dry weight of peak A). On the other hand, peak B was shown to be free of lipopolysaccharide, and 100% of its dry weight consisted of protein and RNA.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101464      PMCID: PMC421960          DOI: 10.1128/iai.21.1.76-86.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Biological properties of an immunogenic pneumococcal subcellular preparation.

Authors:  H C Thompson; T K Eisenstein
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Preparation and biological properties of a chemically modified Escherichia coli endotoxin of high immunogenic potency and low toxicity.

Authors:  H NOLL; A I BRAUDE
Journal:  J Clin Invest       Date:  1961-11       Impact factor: 14.808

3.  Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

Authors:  P Hoops; N E Prather; J Berry; J M Ravel
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

4.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

5.  Chemically-modified crude endotoxins as possible typhoid vaccines.

Authors:  T G Pistole; S Marcus
Journal:  Immunol Commun       Date:  1973

6.  Determination of protein: a modification of the Lowry method that gives a linear photometric response.

Authors:  E F Hartree
Journal:  Anal Biochem       Date:  1972-08       Impact factor: 3.365

7.  Extraction and isolation of individual ribosomal proteins from Escherichia coli.

Authors:  S Fogel; P S Sypherd
Journal:  J Bacteriol       Date:  1968-08       Impact factor: 3.490

8.  The slime of Pseudomonas aeruginosa: biological characterization and possible role in experimental infection.

Authors:  J W Sensakovic; P F Bartell
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

9.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

10.  Serum-mediated resistance induced with immunogenic preparations of Salmonella typhimurium.

Authors:  M R Venneman; L J Berry
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

View more
  15 in total

1.  Immunogenicity of ribosomes from enzymatically lysed Streptococcus pyogenes.

Authors:  B A Green; W Johnson
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

2.  Kinetic analysis of microbe opsonification based on stimulated polymorphonuclear leukocyte oxygenation activity.

Authors:  R C Allen; M M Lieberman
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

3.  Role of outer envelope contamination in protection elicited by ribosomal preparations against Neisseria gonorrhoeae infection.

Authors:  M D Cooper; M J Wannemuehler; R D Miller; M F Fedyk
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

4.  Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.

Authors:  M M Lieberman; D C McKissock; G L Wright
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

5.  Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; C P van Boven
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

6.  Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  P B Fernandes; C Kim; K R Cundy; N N Haung
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

7.  Immunogenicity of ribosomal preparations from Neisseria gonorrhoeae.

Authors:  M D Cooper; R P Tewari; D V Bowser
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

8.  Immunoprotective activity of capsular polysaccharide in Klebsiella pneumoniae ribosomal preparations does not involve ribonucleic acid.

Authors:  M M Riottot; J M Fournier
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

9.  Candida albicans-induced agglutinin and immunoglobulin E responses in mice.

Authors:  G E Winterrowd; J E Cutler
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

10.  Ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; P J Lemmens; C P van Boven
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.